Drug Profile
Research programme: CCR2 antagonists - Incyte/Pfizer
Alternative Names: INCB-3344Latest Information Update: 14 Mar 2012
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Developer Incyte Corporation; Pfizer
- Class Small molecules
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatic fibrosis; Inflammation; Rheumatoid arthritis
Most Recent Events
- 14 Mar 2012 Discontinued - Preclinical for Hepatic fibrosis in USA (unspecified route)
- 14 Mar 2012 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 14 Mar 2012 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)